Equities researchers at HC Wainwright assumed coverage on shares of Vivani Medical (NASDAQ:VANI – Get Free Report) in a note issued to investors on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 138.10% from the company’s previous close.
Vivani Medical Price Performance
VANI stock opened at $1.26 on Thursday. Vivani Medical has a twelve month low of $0.84 and a twelve month high of $7.80. The company has a market cap of $69.62 million, a P/E ratio of -2.68 and a beta of 3.20. The business has a fifty day moving average of $1.22 and a 200-day moving average of $1.37.
Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02.
About Vivani Medical
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Featured Articles
- Five stocks we like better than Vivani Medical
- Stock Splits, Do They Really Impact Investors?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Where to Find Earnings Call Transcripts
- MarketBeat Week in Review – 11/4 – 11/8
- How to Invest in the FAANG Stocks
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
